| 000 | 01541 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515193451.0 | ||
| 264 | 0 | _c20100224 | |
| 008 | 201002s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdp472 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOverkleeft, E N M | |
| 245 | 0 | 0 |
_aNephrotic syndrome caused by the angiogenesis inhibitor sorafenib. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cJan 2010 |
||
| 300 |
_a184-5 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Letter | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aBenzenesulfonates _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xtherapeutic use |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNephrotic Syndrome _xchemically induced |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 | _aPhenylurea Compounds |
| 650 | 0 | 4 |
_aPyridines _xadverse effects |
| 650 | 0 | 4 |
_aPyrroles _xtherapeutic use |
| 650 | 0 | 4 | _aSorafenib |
| 650 | 0 | 4 | _aSunitinib |
| 700 | 1 | _aGoldschmeding, R | |
| 700 | 1 | _avan Reekum, F | |
| 700 | 1 | _aVoest, E E | |
| 700 | 1 | _aVerheul, H M W | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 21 _gno. 1 _gp. 184-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdp472 _zAvailable from publisher's website |
| 999 |
_c19277746 _d19277746 |
||